

November 1, 2016



Pieris Pharmaceuticals to Host Third Quarter 2016 Investor Call and Corporate Update on November 10, 2016

BOSTON, MA -- (Marketwired) -- 11/01/16 -- **Pieris Pharmaceuticals, Inc.** (NASDAQ: PIRS), a clinical stage biotechnology company advancing novel biotherapeutics through its proprietary [Anticalin](#)[®] technology platform for cancer and other diseases, will host a third quarter 2016 investor conference call on Thursday, November 10, 2016 at 10:00 AM (EST) to discuss financial results and provide a corporate update.

To access the call, participants may dial 877-407-8920 (US & Canada) or 412-902-1010 (International) at least 10 minutes prior to the start of the call.

An archived replay of the call will be available by dialling 877-660-6853 (US & Canada) or 201-612-7415 (International) and providing the Conference ID #: 13603006.

About Pieris

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin[®] protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin[®] is registered trademarks of Pieris. For more information, visit www.pieris.com. Anticalin[®], Anticalins[®] are registered trademarks of Pieris.

Company Contact:

Pieris Pharmaceuticals, Inc.
Darlene Deptula-Hicks
SVP & Chief Financial Officer
+1-603-553-5803
deptula@pieris.com

Investor Relations Contact:

The Trout Group
Thomas Hoffmann
+1-646-378-2931
thoffmann@troutgroup.com

Media Inquiries:

Gretchen Schweitzer

+49 172 861 8540

gschweitzer@macbiocom.com

Source: Pieris Pharmaceuticals, Inc.